Active, not recruitingPhase 1NCT06622226
A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Studying Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ono Pharmaceutical Co. Ltd
- Principal Investigator
- Project LeaderOno Pharmaceutical Co. Ltd
- Intervention
- ONO-7018(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2029
Study locations (6)
- Nagoya City University Hospital, Nagoya, Aichi-ken, Japan
- National Hospital Organization Shibukawa Medical Center, Shibukawa-shi, Gunma, Japan
- Hiroshima Red Cross Hospital Atomic-bomb Survivors Hospital, Hiroshima, Hiroshima, Japan
- National Hospital Organization Sendai Medical Center, Sendai, Miyagi, Japan
- The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
- National Hospital Organization Osaka National Hospital, Osaka, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06622226 on ClinicalTrials.govOther trials for Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT07283822Amping up With PemJAKSeda S. Tolu
- RECRUITINGNANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT06854003BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaChristine Ryan
- RECRUITINGPHASE1NCT06522932PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T TherapyMichael Randall
- RECRUITINGPHASE1NCT06420089CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Vittoria Biotherapeutics
- RECRUITINGPHASE1NCT06484985Study of AXT-1003 in Subjects With Advanced Malignant Tumors.Axter Therapeutics (Beijing) Co., Ltd